CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $901 | +149.6% | 19,856 | +208.4% | 0.01% | +150.0% |
| Q2 2023 | $361 | +511.9% | 6,439 | +394.5% | 0.00% | – |
| Q1 2023 | $59 | +51.3% | 1,302 | +36.1% | 0.00% | – |
| Q4 2022 | $39 | -100.0% | 957 | -93.8% | 0.00% | -100.0% |
| Q3 2022 | $1,010,000 | +8.6% | 15,456 | +1.0% | 0.01% | +14.3% |
| Q2 2022 | $930,000 | +0.5% | 15,302 | +3.8% | 0.01% | +16.7% |
| Q1 2022 | $925,000 | +250.4% | 14,737 | +323.0% | 0.01% | +500.0% |
| Q4 2021 | $264,000 | -82.9% | 3,484 | -65.5% | 0.00% | -92.3% |
| Q4 2020 | $1,544,000 | – | 10,084 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |